Ngā hua rapu - Ashley M. Hopkins
- E whakaatu ana i te 1 - 18 hua o te 18
-
1
Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials mā Michael J. Sorich, Andrew Rowland, Christos S. Karapetis, Ashley M. Hopkins
I whakaputaina 2019Artigo -
2
-
3
-
4
Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab mā Ashley M. Hopkins, Ganessan Kichenadasse, Elizabeth Garrett–Mayer, Christos S. Karapetis, Andrew Rowland, Michael J. Sorich
I whakaputaina 2020Artigo -
5
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer mā Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins, Michael J. Sorich
I whakaputaina 2019Artigo -
6
-
7
Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver Disease mā Lauren A. Newman, Zivile Useckaite, Jillian G. Johnson, Michael J. Sorich, Ashley M. Hopkins, Andrew Rowland
I whakaputaina 2022Artigo -
8
The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy mā Sarah Badaoui, Adel Shahnam, Ross A. McKinnon, Ahmad Y. Abuhelwa, Michael J. Sorich, Ashley M. Hopkins
I whakaputaina 2022Artigo -
9
Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials mā Ashley M. Hopkins, Sarah Badaoui, Ganessan Kichenadasse, Christos S. Karapetis, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich
I whakaputaina 2022Artigo -
10
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers mā Ashley M. Hopkins, Andrew Rowland, Ganessan Kichenadasse, Michael D. Wiese, Howard Gurney, Ross A. McKinnon, Christos S. Karapetis, Michael J. Sorich
I whakaputaina 2017Revisão -
11
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150 mā Ashley M. Hopkins, Ganessan Kichenadasse, Ross A. McKinnon, Ahmad Y. Abuhelwa, Jessica M. Logan, Sarah Badaoui, Christos S. Karapetis, Andrew Rowland, Michael J. Sorich
I whakaputaina 2021Artigo -
12
Comparative Risk of Gout Flares When Initiating or Escalating Various Urate‐Lowering Therapy: A Systematic Review With Network Meta‐Analysis mā Dorsa Maher, Emily Reeve, Ashley M. Hopkins, Jiun Ming Tan, Mahsa Tantiongco, Nagham Ailabouni, Richard Woodman, Lisa K. Stamp, David Bursill, Susanna Proudman, Michael D. Wiese
I whakaputaina 2024Revisão -
13
The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data mā Natansh D. Modi, Eugene Tan, Andrew Rowland, Bogda Koczwara, Ahmad Y. Abuhelwa, Ganessan Kichenadasse, Ross A. McKinnon, Michael D. Wiese, Michael J. Sorich, Ashley M. Hopkins
I whakaputaina 2021Artigo -
14
Tumour Mutational Burden and Immune Checkpoint Inhibitor Response in Non-small Cell Lung Cancer: A Continuous Modelling Approach mā Michael J. Sorich, Arkady T. Manning‐Bennett, Lee X. Li, Adel Shahnam, Ganessan Kichenadasse, Christos S. Karapetis, Ahmad Y. Abuhelwa, Ross A. McKinnon, Andrew Rowland, Ashley M. Hopkins
I whakaputaina 2025Artigo -
15
Current safeguards, risk mitigation, and transparency measures of large language models against the generation of health disinformation: repeated cross sectional analysis mā Bradley D. Menz, Nicole M. Kuderer, Stephen Bacchi, Natansh D. Modi, Benjamin Chin‐Yee, Tiancheng Hu, Ceara Rickard, Mark Haseloff, Agnès Vitry, Ross A. McKinnon, Ganessan Kichenadasse, Andrew Rowland, Michael J. Sorich, Ashley M. Hopkins
I whakaputaina 2024Artigo -
16
Generative AI Chatbots for Reliable Cancer Information: Evaluating web-search, multilingual, and reference capabilities of emerging large language models mā Bradley D. Menz, Natansh D. Modi, Ahmad Y. Abuhelwa, Warit Ruanglertboon, Agnès Vitry, Yuan Gao, Lee X. Li, Rakchha Chhetri, Benjamin Chu, Stephen Bacchi, Ganessan Kichenadasse, Adel Shahnam, Andrew Rowland, Michael J. Sorich, Ashley M. Hopkins
I whakaputaina 2025Artigo -
17
Exploring the role of sporadic BRAF and KRAS mutations during colorectal cancer pathogenesis: A spotlight on the contribution of the endosome-lysosome system mā Jingying Tang, Giang T. Lam, Robert D. Brooks, Mark A. Miles, Zivile Useckaite, I. R. Johnson, Benjamin S.‐Y. Ung, Carmela Martini, Litsa Karageorgos, Shane M. Hickey, Stavros Selemidis, Ashley M. Hopkins, Andrew Rowland, Ryash Vather, John O’Leary, Doug A. Brooks, Maria C. Caruso, Jessica M. Logan
I whakaputaina 2024Revisão -
18
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority... mā Janet Dunn, Peter Donnelly, Nada Elbeltagi, Andrea Marshall, Ashley M. Hopkins, Alastair M. Thompson, Riccardo A. Audisio, Sarah E. Pinder, David Cameron, Sue M. Hartup, Lesley Turner, Annie Young, Helen M. Higgins, Eila Watson, Sophie Gasson, Peter Barrett‐Lee, Claire Hulme, Bethany Shinkins, Peter Hall, Andrew Evans
I whakaputaina 2025Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Medicine
Internal medicine
Cancer
Oncology
Immunotherapy
Atezolizumab
Lung cancer
Nivolumab
Biochemistry
Biology
Clinical trial
Confidence interval
Adverse effect
Chemotherapy
Computer science
Hazard ratio
Randomized controlled trial
Bioinformatics
Biomarker
Breast cancer
Cancer research
Concomitant
Environmental health
Enzyme
Pathology
Philosophy
Proton-pump inhibitor
Surgery
Absolute risk reduction
Alcoholic hepatitis